Quantum BioPharma Ltd. Announces Corporate Updates

Newsfile Corp.

Toronto, Ontario--(Newsfile Corp. - October 29, 2025) - Quantum BioPharma Ltd. (FSE: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announces, as approved by the shareholders of the Company at the annual general and special meeting of shareholders held on September 26, 2025, a non-brokered private placement of up to 30 class A multiple voting shares of the Company ("Class A Multiple Voting Shares") at a price of $25 per Class A Multiple Voting Shares, for aggregate gross proceeds of up to $750 (the "Offering"). The Company expects that the entirety of the Offering will be subscribed for by entities beneficially owned or controlled by Zeeshan Saeed and Anthony Durkacz, being the existing holders of Class A Multiple Voting Shares.

When the Company initially went public in 2018, the voting rights attached to the Class A Multiple Voting Shares equalled 75.87% of the aggregate voting rights attached to the Class A Multiple Voting Shares and Class B Subordinate Voting Rights. As a result of issuances of class B subordinate voting shares (the "Class B Subordinate Voting Shares") over the intervening 7 years, that percentage has declined 46.52%. The Company has determined that it would be in its best interests to proceed with the Offering, which, if fully subscribed, would result in the voting rights attached to the Class A Multiple Voting Shares increasing to 75.27%, which returns those voting rights to nearly the same percentage as when the Company initially went public. The board of directors of the Company determined that the Offering was in the best interests of the Company and executed a board resolution approving the same on October 29, 2025. In its decision-making process, the board of directors had informal discussions excluding Messrs. Saeed and Durkacz to discuss the Offering, it reviewed the Company's articles, and it reviewed the implications of issuing additional Class A Multiple Voting Shares. Zeeshan Saeed and Anthony Durkacz abstained from this vote with respect to their interest in the resolution, in accordance with section 132(5) of the Business Corporations Act (Ontario) (the "OBCA"). In accordance with the OBCA, all the directors were required to sign the authorizing resolution in order for the Offering to be valid as if passed at a meeting of the directors of the Company, however, the signatures of each of Zeeshan Saeed and Anthony Durkacz do not constitute a vote by the insider as a director to approve the Offering. The Offering was unanimously approved by the directors of the Company entitled to vote thereon. All Class A Multiple Voting Shares issued pursuant to the Offering will be subject to hold periods of four months and a day from the date of closing in accordance with applicable securities laws of Canada. The Company intends to use the proceeds of the Offering for general working capital purposes

MI 61-101 Disclosure

It is anticipated that the Offering will be fully subscribed by Xorax Family Trust ("Xorax"), a trust of which Zeeshan Saeed, the Chief Executive Officer and Co-Chairman of the Company is a beneficiary, and Fortius Research and Trading Corp. ("Fortius"), a corporation of which Anthony Durkacz, a director of the Company is a director, is expected to purchase all the Class A Multiple Voting Shares issued pursuant to the Offering. The participation by such insiders is considered a "related-party transaction" within the meaning of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company expects that any such resulting related party transaction will be exempt from the formal valuation requirement and minority shareholder approval requirements of MI 61-101 based on the exemptions under sections 5.5(a) and 5.7(1)(a) of MI 61-101 as the fair market value of the Class A Multiple Voting Shares being purchased will not exceed 25% of the Company's market capitalization. The Company expects that the closing of the Offering will occur within 21 days of this announcement and that it will not file a material change report in respect of the related party transaction at least 21 days before the closing date. The Company deems this circumstance reasonable and necessary in order to complete the Offering in an expeditious manner.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws.

Early Warning Disclosure

This press release is being issued in accordance with the requirements of National Instrument 62-103 - The Early Warning System and Related Take-Over Bid and Insider Reporting Issues ("NI 62-103"), in connection with the filing of the Early Warning Report by Anthony Durkacz (the "Transferor"), whose registered address is 2045 Lakeshore Boulevard West, Suite 3006, Toronto, Ontario M6V 2Z6, in respect of the transfer of 77,000 Class B Subordinate Voting Shares of Quantum BioPharma, whose head office is at 1 Adelaide Street East, Suite 801, Toronto, Ontario M5C 2V9, to another individual on October 29, 2025 (the "Transfer") pursuant to a private agreement entered into to give effect to a matrimonial settlement (the "Settlement Agreement"). The 77,000 Class B Subordinate Voting Shares were transferred for no cash consideration.

Prior to the Transfer, the Transferor, together with Fortius Research and Trading Corp. and First Republic Capital Corporation (collectively, the "Joint Actors"), had ownership or control over an aggregate of 6 Class A Multiple Voting Shares and 113,495 Class B Subordinate Voting Shares, representing approximately 50% of the outstanding Class A Multiple Voting Shares, 2.97% of the outstanding Class B Subordinate Voting Shares, and 24.85% of the voting rights attached to all of the Company's outstanding voting securities on a non-diluted basis. Each Class A Multiple Voting Share carries 276,660 votes and each Class B Subordinate Voting Share carries one vote at meetings of shareholders of the Company.

Following the Transfer, the Transferor, together with the Joint Actors, has ownership or control over an aggregate of 6 Class A Multiple Voting Shares and 36,495 Class B Subordinate Voting Shares, representing approximately 50% of the outstanding Class A Multiple Voting Shares, 0.96% of the outstanding Class B Subordinate Voting Shares, and 23.77% of the voting rights attached to all of the Company's outstanding voting securities on a non-diluted basis.

In addition, the Transferor holds 32,000 restricted share units ("RSUs") and 7,000 options ("Options"), each of which upon vesting are exercisable or settle into one Class B Subordinate Voting Share. On a partially diluted basis, assuming the settlement of all RSUs and Options, the Transferor and the Joint Actors would haves ownership or control over an aggregate of 6 Class A Multiple Voting Shares and 75,495 C Class B Subordinate Voting Shares, representing approximately 50% of the outstanding Class A Multiple Voting Shares, 1.96% of the outstanding Class B Subordinate Voting Shares, and 24.18% of the voting rights attached to all of the Company's outstanding voting securities.

The Transfer was effected privately pursuant to the Settlement Agreement. The Transferor may, from time to time and at any time, depending on market conditions, the business and prospects of the Company, and other relevant factors, evaluate his investment in the Company and may acquire additional securities or dispose of securities through market transactions, private agreements, treasury issuances, or otherwise.

A copy of the Early Warning Report being filed by the Transferor may be obtained on the Company's SEDAR+ profile at www.sedarplus.ca or by emailing adurkacz@quantumbiopharma.com or calling (833) 571-1811.

About Quantum BioPharma Ltd.

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Celly Nutrition Corp, now Unbuzzd Wellness Inc., led by industry veterans. Quantum BioPharma retains ownership of 20.10% (as of June 30, 2025) of Unbuzzd Wellness Inc. at www.unbuzzd.com. The agreement with Unbuzzd Wellness Inc. also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

For more information, visit www.quantumbiopharma.com.

Forward-Looking Information

This press release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable securities laws. Any statements that are contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "plans", "expects", "expected", "scheduled", "estimates", "intends", "anticipates", "hopes", "planned" or "believes", or variations of such words and phrases, or states that certain actions, events or results "may", "could", "would", "might", "potentially" or "will" be taken, occur or be achieved. More particularly, and without limitation, this press release contains forward-looking statements contained in this press release includes, but is not limited to, statements that address activities, events or developments that the Company expects or anticipates will or may occur in the future including the closing dates of the Offering, the size of the Offering, proposed use of proceeds of the Offering, the subscribers of the Offering including the expected participation of certain related parties, the Company's exemption from certain requirements of MI 61-101, the receipt of approvals for the Offering, and the timing of and receipt of regulatory approval for the Offering.

Further information regarding factors that may cause actual results to differ materially are included in the Company's annual and other reports filed from time to time with the Canadian Securities Administrators on SEDAR+ (www.sedarplus.ca) and with the SEC on EDGAR (www.sec.gov), including the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2024, the Prospectus and Registration Statement, each under the heading "Risk Factors". This list of risk factors should not be construed as exhaustive. Readers are cautioned that events or circumstances could cause results to differ materially from those predicted, forecasted or projected. The forward-looking statements contained in this document speak only as of the date of this document. Quantum BioPharma does not undertake any obligation to publicly update or revise any forward-looking statements or information contained herein, except as required by applicable laws. The forward-looking statements contained in this document are expressly qualified by this cautionary statement.

The reader is urged to refer to additional information relating to Quantum BioPharma, including its annual information form, can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the SEC's website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.

Contacts:

Quantum BioPharma Ltd.

Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board

Email: Zsaeed@quantumbiopharma.com

Telephone: (833) 571-1811

Investor Relations

Investor Relations: IR@QuantumBioPharma.com

General Inquiries: info@QuantumBioPharma.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/272495

Risk Warnings and Disclaimers

You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.

Add to Favorites

Three Biotech Companies Redefining Value Creation Through Dual Strategies

Acceswire

Coeptis Therapeutics Holdings, Inc. Warrants

+6.25%

Medicus Pharma Ltd. Common Stock

-0.49%

Medicus Pharma Ltd. Warrant

+6.80%

The Rise of Multi-Dimensional Biotech

BRISTOL, TN, TN / ACCESS Newswire / October 14, 2025 / For decades, biotechnology investing was a binary game - a single trial failure could erase years of progress and billions in shareholder value. Yet a new generation of public life sciences companies is rewriting that equation by diversifying not just products, but business models.

Medicus Pharma Ltd. , Coeptis Therapeutics Holdings , and Quantum BioPharma Ltd. each represent a new archetype: the dual-engine biotech. They combine credible therapeutic innovation with a second, strategically differentiated platform - whether digital, diagnostic, or delivery-based - designed to create value independent of any single molecule.

Medicus Pharma: A Three-Track Clinical Portfolio Built for Risk Mitigation

Most biotech companies live or die on one program. Medicus Pharma is building three.

Dermatology: Its lead program, Skinject, uses a dissolvable microneedle array to deliver doxorubicin directly to basal-cell carcinomas - a $9 billion market projected by 2034. FDA feedback confirmed the therapy qualifies for the expedited 505(b)(2) pathway, letting Medicus leverage existing safety data and shorten development timelines.
Oncology / Urology: The Teverelix acquisition brought a next-generation GnRH antagonist that reduces cardiovascular risk for prostate-cancer patients. Meta-analyses show 40-50 percent fewer major cardiac events compared with legacy agonists.
Vaccine Platform: A memorandum with HelixNano adds an exploratory third pillar - pairing Medicus's microneedle system with mRNA vaccine delivery.

By distributing development risk across three therapeutic areas - dermatology, oncology, and vaccines - Medicus positions itself to capture upside from multiple market verticals while reducing binary failure exposure.

Coeptis Therapeutics: Engineering an $800 Million Dual-Sector Enterprise

Coeptis Therapeutics has turned diversification into a valuation driver. SEC filings assign roughly $660 million to its core technology division and $75 million to a planned biotech spin-out - together forming an $835 million dual-sector framework.

Life Sciences Division: The company develops advanced cell-therapy platforms, including DVX201 (allogeneic NK cell therapy) and SNAP-CAR, a universal multi-antigen CAR technology licensed from the University of Pittsburgh.
Technology Division: Parallel to its clinical work, Coeptis acquired AI-driven marketing and robotic-automation software from NexGenAI Solutions Group - a strategic bridge between biotech operations and digital infrastructure.

That structural duality - combining wet-lab science with digital productivity - translates into operational leverage and potential tax efficiencies. The planned oncology spin-out, to be distributed 1:1 to shareholders, aligns management with long-term shareholder return, not just clinical milestones.

Quantum BioPharma: The Digitally Engineered Issuer

Quantum BioPharma stands at the frontier where biotechnology meets financial technology.

Scientific Core: The Lucid-MS program targets remyelination and neuroprotection in multiple sclerosis through an innovative PET-imaging biomarker strategy with Massachusetts General Hospital.
Consumer Health Arm: Via its subsidiary Celly Nu, Quantum earns a perpetual royalty stream from unbuzzd™, a clinically validated beverage that accelerates alcohol metabolism - providing non-dilutive recurring revenue.
Digital Market Infrastructure: The company's dual listing on Upstream, a blockchain-enabled trading platform, gives it same-day settlement and global investor reach - a structural innovation few biotech peers can match.

Quantum embodies the concept of the programmable balance sheet - integrating science, liquidity, and data transparency into a cohesive corporate architecture.

The Common Thread: Structural Diversification as Shareholder Strategy

Each of these companies breaks from the single-asset biotech mold by embedding a secondary engine into its business model:

Company	Core Focus	Secondary Engine	Shareholder Value Lever
Medicus Pharma	Oncology & Dermatology	Microneedle & Vaccine Platform	Multi-market optionality
Coeptis Therapeutics	Cell Therapy	AI & Automation Technology	Dual-sector valuation and tax efficiency
Quantum BioPharma	Neuroscience	Digital / Blockchain Market Access	Liquidity & transparent balance sheet

This hybridization is more than diversification. It's a shift toward anti-fragile biotech models - enterprises designed to create value whether through clinical success, digital scalability, or asset monetization.

The Institutional Takeaway

Investors increasingly reward companies that can demonstrate resilience across regulatory, technological, and capital cycles. Medicus, Coeptis, and Quantum are defining that playbook: pairing disciplined science with engineered optionality.

In a sector where binary outcomes have long dictated fortunes, these issuers are showing that the next generation of biotech isn't about a single cure - it's about constructing a balance sheet that can survive the wait for one.

Quantum BioPharma: Engineering the Digital Balance Sheet in Life Sciences A Vanderbilt Report View

Acceswire

A New Model for the Modern Issuer

BRISTOL, TN / ACCESS Newswire / October 7, 2025 / Quantum BioPharma Ltd. (FRA:0K91) is quietly redrawing the boundaries of what a biotechnology company can be. The company has evolved beyond traditional R&D into a diversified enterprise-one that integrates clinical innovation, consumer health commercialization, and advanced market infrastructure.

In an era where science, data, and capital efficiency intersect, Quantum BioPharma represents a new category of public issuer: the digitally engineered life sciences company.

From Molecules to Markets

Quantum's foundation remains firmly rooted in neuroscience. Its flagship program, Lucid-MS (Lucid-21-302), is a proprietary neuroprotective compound targeting demyelination and neurodegeneration in multiple sclerosis (MS).

In collaboration with Massachusetts General Hospital, Quantum is conducting a pioneering imaging study using the PET tracer [^18F]3F4AP to monitor remyelination in vivo-a biomarker-driven approach that could redefine how neurorepair is measured and quantified.

This clinical focus demonstrates the company's disciplined scientific core. But Quantum's broader strategy reveals something more ambitious: an integrated approach to how research, data, and capital are aligned for long-term growth.

Reframing the Corporate DNA

Quantum has aligned its operations around three complementary verticals:

Biopharmaceutical Development - advancing Lucid-MS and related neurological compounds through translational research.
Consumer Health Commercialization - through Celly Nu, developer of the unbuzzd™ beverage, a clinically validated formulation that supports faster alcohol metabolism and cognitive recovery. Quantum retains pharmaceutical rights to the formulation and earns a royalty stream of 7 percent on sales until USD $250 million is paid, and 3 percent thereafter in perpetuity.
Market Access Innovation - utilizing modern trading and settlement technology to expand shareholder reach and enhance transparency for international investors.

In January 2025, Quantum's shares were approved for dual listing on Upstream, a regulated digital exchange environment designed for near-instant settlement and wider global participation. The listing underscores Quantum's commitment to accessibility, speed, and modernization within the public-market ecosystem.

A Blueprint for the Modern Capital Era

Quantum's approach goes beyond therapeutic innovation-it reflects a holistic view of how public companies can adapt to a new financial architecture. The company's leadership views its next-generation listing strategy and capital design as extensions of the same precision that drives its research pipeline: structure, clarity, and data integrity.

By modernizing how its equity trades and how investors engage with the company, Quantum is creating what The Vanderbilt Report defines as a "digital balance-sheet framework"-a structure that supports transparency, efficiency, and long-term shareholder confidence.

A Convergence of Science and Strategic Capital

Quantum BioPharma stands at the intersection of two powerful growth curves:

The global biotechnology market, projected to exceed $3 trillion by 2030, driven by advances in neurodegenerative and regenerative medicine.
The rise of next-generation market infrastructure, which is transforming how global issuers connect with investors and measure performance in real time.

By aligning these forces, Quantum BioPharma is building what The Vanderbilt Report identifies as a next-generation issuer model-one where scientific credibility, operational transparency, and shareholder connectivity define enterprise value.

The Institutional View

For investors and analysts, Quantum BioPharma represents more than a biotech story. It's a forward signal of how public companies will evolve as science, technology, and capital markets continue to merge.

From its neurorepair pipeline to its commitment to transparent, technology-enabled investor access, the company is crafting a framework that others may soon follow-a model of resilience, data-driven governance, and investor alignment in an era defined by rapid information flow.

In a market increasingly shaped by precision, speed, and trust, Quantum BioPharma is positioning itself not just as a participant-but as a prototype.

See the full report at The Vanderbilt Report

About The Vanderbilt Report

The Vanderbilt Report was founded with a clear mission - to redefine how a new generation engages with Wall Street. We deliver trusted market intelligence, founder insights, and institutional-grade analysis designed for today's dynamic investment landscape. By blending traditional reporting with real-time data and narrative-driven coverage, The Vanderbilt Report provides clarity and credibility for investors, funds, and public companies navigating the modern markets.

Compliance Note:

This announcement is based on Quantum BioPharma Ltd.'s public filings and official disclosures, including its clinical updates, market announcements, and investor communications. It does not constitute investment advice, a solicitation, or a recommendation to buy or sell securities.

CONTACT

Vanderbilt Report Media Relations

Kristen Owens

info@vanderbiltreport.com

SOURCE: Quantum BioPharma Ltd

View the original press release on ACCESS Newswire

Risk Warnings and Disclaimers

Add to Favorites

Quantum BioPharma Announces Corporate Updates

Newsfile Corp.

Toronto, Ontario--(Newsfile Corp. - September 26, 2025) - Quantum BioPharma Ltd. (FSE: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announces the following corporate updates:

Grant of Restricted Stock Units

The Company's board of directors (the "Board") authorized and approved the grant of restricted share units (each, an "RSU") pursuant to the Company's omnibus equity incentive plan (the "Equity Incentive Plan"). The Company granted 32,000 RSUs to each of Zeeshan Saeed, Anthony Durkacz and Donal Carroll (the "RSU Grant"). The RSUs granted vest upon the compilation of data which would enable the drafting of a Phase 2 MS Study.

Stock Options Grant

In addition, the Company granted 98,000 options (the "Options") to acquire Class B subordinate voting shares in the capital of the Corporation (the "Class B Shares") at C$24.50 per Class B Share, pursuant to the Equity Incentive Plan to certain directors, officers, employees and consultants (the "Option Grant"). The Options granted vest immediately and expire September 24, 2030.

Statutory Hold Period and Restrictions on Resale

The Options and RSUs (and any Class B Shares issuable upon their settlement or exercise) are subject to a statutory hold period of four months and one day, and were not registered under the U.S. Securities Act and are not permitted to be offered or sold within the United States absent such registration or an applicable exemption from the registration requirements therein.

Related Party Transaction

The RSU Grant and the Option Grant, as they relate to the directors of the Company, constitutes a "related party transaction", as such term is defined in Multilateral Instrument 61-101 - Protection of Minority Shareholders in Special Transactions ("MI 61-101") due to the grants to the directors, who are members of the Board, and would require the Company to receive minority shareholder approval for, and obtain a formal valuation for the subject matter of, the transaction in accordance with MI 61-101, prior to the completion of the RSU Grant and the Option Grant, as they relate to the directors of the Company. In its consideration and approval of the RSU Grant and the Option Grant, as they relate to the directors of the Company, the Board determined that the RSU Grant and the Option Grant, as they relate to the directors of the Company, were exempt from the formal valuation and minority approval requirements of MI 61-101. The Company has relied on exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in respectively, sections 5.5(a) and 5.7(1)(a) of MI 61-101 in respect of related party participation in the RSU Grant and the Option Grant, as they relate to the directors of the Company, as neither the fair market value (as determined under MI 61-101) of the subject matter of, nor the fair market value of the consideration for, the transaction, insofar as it involved the related parties, exceeded 25% of the Company's market capitalization (as determined under MI 61- 101).

The Company did not file a material change report more than 21 days before the RSU Grant and the Option Grant, as they relate to the directors of the Company, because the details of the grants to related parties to the Company were not settled until shortly prior to the grants, and the Company wished to proceed on an expedited basis for business reasons.

About Quantum BioPharma Ltd.

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Celly Nutrition Corp. ("Celly Nutrition"), now Unbuzzd Wellness Inc., led by industry veterans. Quantum BioPharma retains ownership of 20.10% (as of June 30, 2025) of Unbuzzd Wellness Inc. at www.unbuzzd.com. The agreement with Unbuzzd Wellness Inc. also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

For more information visit www.quantumbiopharma.com.

Forward-Looking Information

This press release contains forward-looking statements under applicable securities laws, identified by terms like "may," "should," "anticipate," "expect," "potential," "believe," or "intend." These statements, based on assumptions and expected future events, involve risks and uncertainties that may cause actual results to differ materially from those expressed. For more details on risks, see Quantum BioPharma's filings on SEDAR+ (www.sedarplus.ca) and EDGAR (www.sec.gov). Readers should not rely unduly on these statements, as there is no assurance that plans or expectations will occur. The Company assumes no obligation to update these statements except as required by law.

The reader is urged to refer to additional information relating to Quantum BioPharma, including its annual information form, which can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission's website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.

Contacts:

Quantum BioPharma Ltd.

Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board

Email: Zsaeed@quantumbiopharma.com

Telephone: (833) 571-1811

Investor Relations

Investor Relations: IR@QuantumBioPharma.com

General Inquiries: info@QuantumBioPharma.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/268222

Risk Warnings and Disclaimers

Add to Favorites

Quantum BioPharma Announces Update to Previously Announced Private Placement

Newsfile Corp.

Toronto, Ontario--(Newsfile Corp. - August 11, 2025) - Quantum BioPharma Ltd. (FSE: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that further to its press release dated June 27, 2025, the Company will be seeking shareholder approval of its non-brokered private placement of class A multiple voting shares ("MVS") for aggregate gross proceeds of up to $600 (the "Offering") at its upcoming annual general and special meeting being held on September 26, 2025 (the "Meeting").

The Company expects that the entirety of the Offering will be subscribed for by the existing holders of MVS. The Offering is expected to close on or about September 26, 2025, subject to receiving the requisite shareholder approval at the Meeting. All securities issued pursuant to the Offering are subject to a statutory hold period of four months plus a day from issuance in accordance with applicable securities laws of Canada. The Company intends to use the proceeds of the Offering for general working capital purposes. For further details on the Offering, including Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions disclosure, refer to the Company's press release dated June 27, 2025.

The Company has filed a material change report more than 21 days before the expected closing of the Offering in accordance with MI 61-101 on its SEDAR+ profile.

About Quantum BioPharma

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), led by industry veterans. Quantum BioPharma retains ownership of 20.11% (as of March 31, 2025) of Unbuzzd Wellness Inc. The agreement with Unbuzzd Wellness Inc. also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

For more information on Quantum BioPharma, please visit www.quantumbiopharma.com.

This press release contains certain "forward-looking statements" within the meaning of Canadian securities law. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, identified by words or phrases such as "believes", "anticipates", "expects", "is expected", "scheduled", "estimates", "pending", "intends", "plans", "forecasts", "targets", or "hopes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "will", "should" "might", "will be taken", or "occur" and similar expressions) are not statements of historical fact and may be forward-looking statements. Forward-looking information herein includes, but is not limited to, statements that address activities, events or developments that the Company expects or anticipates will or may occur in the future, including the Meeting, Offering and subscription to the Offering by insiders of the Company, and anticipated closing date of the Offering.

In making the forward-looking statements in this news release, the Company has applied several material assumptions, including without limitation: the Company's ability to comply with all applicable regulations and laws, including environmental, health and safety laws; receipt of all regulatory approvals; receipt of shareholder approval; the Meeting proceeding as anticipated; the Company having sufficient working capital for future operating activities; the ability of the Company to achieve its business objectives and milestones and the anticipated timing of execution; the Company's ability to continue as a going concern and the Company's ability to use the proceeds from the Offering for the business objectives outlined herein.

The Company cautions that forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made, and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: changes in general economic, business and political conditions, including changes in the financial markets; consents or authorizations required; changes in laws, regulations and policies affecting the Company's operations; currency fluctuations; environmental issues and liabilities; the potential impact of the announcement or consummation of the Offering on relationship, including with regulatory bodies, employees, suppliers, customers and competitors; the inability of the Company to obtain additional financing for continued operations on terms acceptable to the Company; the lack of control over the Company's investees; risks relating to investing in the MVS; risks relating to the use of proceeds from the Offering; volatility in the market price of the shares; dilution of shareholders' holdings; negative operating cash flow; the negative effects of interest rate and exchange rate changes; risks relating to the Company's reliance on key employees; limitations in the liquidity of the MVS; the Company's inability to receive shareholder approval of the Offering at the Meeting; litigation risks; the Company's inability to expand into new business areas and geographic markets; management of growth; and the Company's inability to continue as a going concern.

Except to the extent required by applicable securities laws and the policies of the Canadian Securities Exchange, the Company undertakes no obligation to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors, should change.

The reader is urged to refer to additional information relating to Quantum BioPharma, including its annual information form, can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the SEC's website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.

Contacts

Quantum BioPharma Ltd.

Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board, Quantum BioPharma Ltd.

Email: info@QuantumBioPharma.com

Telephone: (416) 854-8884

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262125

Risk Warnings and Disclaimers

Add to Favorites

Quantum BioPharma stock falls after clinical trial report release

Investing.com

Advanced Micro Devices

Investing.com -- Quantum BioPharma Ltd (NASDAQ:QNTM) stock fell 2.5% following the announcement of its Phase 1 clinical study report for Lucid-MS, a multiple sclerosis treatment candidate.

The company reported that its subsidiary, Huge Biopharma Australia, received the clinical study report (CSR) for its Phase 1 trial evaluating the safety and pharmacokinetics of Lucid-MS in healthy adult participants. According to the report, the multiple ascending dose study showed no safety or tolerability concerns in healthy participants following consecutive daily dosing.

Lucid-MS is described as a first-in-class, non-immunomodulatory, neuroprotective compound with a unique mechanism of action for treating multiple sclerosis. The patented New Chemical Entity has demonstrated the ability to prevent demyelination in preclinical models, a characteristic damage to the myelin sheath surrounding nerve fibers seen in MS and other neurodegenerative diseases.

Dr. Andrzej Chruscinski, Vice-President of Clinical and Scientific Affairs at Quantum BioPharma, stated that the CSR is a critical component for the company’s investigational new drug application with the FDA and will allow them to advance the clinical development of Lucid-MS.

Dr. Lakshmi P. Kotra, Director at Quantum BioPharma and Professor at University of Toronto, who led the discovery of Lucid-MS, added that the company is preparing to launch efficacy trials in patients with MS following these first-in-human studies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Risk Warnings and Disclaimers

Add to Favorites

Quantum BioPharma stock falls after GameStop share purchase

Investing.com

Advanced Micro Devices

+1.44%

Meta Platforms

-0.98%

Investing.com -- Quantum BioPharma Ltd. (NASDAQ:QNTM) stock fell 5.7% after the company announced it purchased 2,000 shares of GameStop Corp . (NYSE:GME) as what it described as a "strategic investment."

The biopharmaceutical company, which focuses on neurodegenerative disorders, said the move aligns with its "commitment to combating market corruption and enhancing shareholder value." According to the announcement, the company views the GameStop acquisition as a step toward deploying capital toward undervalued assets with strong fundamentals.

"The Quantum team and I see the extreme value in GameStop going forward and the deep value the company has with 90% cash and marketable securities on their balance sheet," said Kevin Malone, Board Advisor to Quantum BioPharma.

The company has positioned itself as fighting against market manipulation, citing recent appointments of advocates against naked short selling and its ongoing legal action against CIBC (TSX:CM) World Markets, RBC Dominion Securities, and others. Quantum is seeking damages exceeding $700 million USD for alleged stock price manipulation between January 2020 and August 2024.

In parallel with these efforts, Quantum BioPharma continues to advance its Multiple Sclerosis patented treatment asset and has announced intentions to declare a special dividend of contingent value rights tied to potential litigation settlements.

The company also disclosed it has completed a debt settlement of $40,000 with an arm’s length creditor through the issuance of Class B shares in June and July 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Risk Warnings and Disclaimers

Add to Favorites